Revolo Biotherapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $53.1M
Latest Deal Amount
  • Investors
  • 4

Revolo Biotherapeutics General Information

Description

Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for disease modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis, and inflammatory bowel diseases to get better treatment and faster recovery.

Contact Information

Website
revolobio.com
Formerly Known As
Peptinnovate, Immune Regulation
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • C/o BCS, Windsor House
  • Station Court, Station Road, Great Shelford
  • Cambridge CB22 5NE
  • England, United Kingdom
+44 01438 000000

Revolo Biotherapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Revolo Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 21-Sep-2020 $53.1M 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC 16-May-2018 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC 14-Jun-2017 00.000 00.00 000.00 Completed Clinical Trials - Phase 1
4. Early Stage VC 23-Feb-2016 00.000 00.000 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC 28-Jul-2015 00000 00.000 000.00 Completed Clinical Trials - Phase 1
2. Grant $940K Completed Clinical Trials - Phase 1
1. Angel (individual) 17-Dec-2014 $940K $940K 0000 Completed Clinical Trials - Phase 1
To view Revolo Biotherapeutics’s complete valuation and funding history, request access »

Revolo Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 30,530 $0.000137 $123.68 $123.68 1x $123.68 1.53%
To view Revolo Biotherapeutics’s complete cap table history, request access »

Revolo Biotherapeutics Executive Team (14)

Name Title Board Seat Contact Info
Clare Burgess Ph.D Chief Operating Officer
Perry Calias Chief Development Officer
Roly Foulkes Ph.D Co-Chief Scientific Officer
Peter Greenleaf Chairman
Jeff Myers MD Chief Medical Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Revolo Biotherapeutics Board Members (14)

Name Representing Role Since
Christopher Smith Revolo Biotherapeutics Board Member 000 0000
Clive Page Metellus Board Member 000 0000
Dominik Escher Ph.D Self Chairman 000 0000
Gunnar Walstam Revolo Biotherapeutics Board Member 000 0000
Isaac Cheng MD Morningside Group Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Revolo Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Revolo Biotherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Morningside Group Venture Capital Minority 000 0000 000000 0
24Haymarket Angel Group Minority 000 0000 000000 0
NCL Technology Ventures Venture Capital Minority 000 0000 000000 0
Metellus Family Office Minority 000 0000 000000 0
To view Revolo Biotherapeutics’s complete investors history, request access »